




Decline of Humoral Responses against SARS-CoV-2 Spike in Convalescent Individuals

Guillaume Beaudoin-Bussières,^{a,b} Annemarie Laumaea,^{a,b} Sai Priya Anand,^{a,c} Jérémie Prévost,^{a,b} Romain Gasser,^{a,b} Guillaume Goyette,^a Halima Medjahed,^a Josée Perreault,^d Tony Tremblay,^d Antoine Lewin,^d Laurie Gokool,^a Chantal Morrissette,^a Philippe Bégin,^{a,e} Cécile Tremblay,^{a,b} Valérie Martel-Laferrrière,^{a,b} Daniel E. Kaufmann,^{a,f} Jonathan Richard,^{a,b} Renée Bazin,^d  Andrés Finzi^{a,b,c}

^aCentre de Recherche du CHUM, Quebec, Canada

^bDépartement de Microbiologie, Infectiologie et Immunologie, Université de Montréal, Montreal, Quebec, Canada

^cDepartment of Microbiology and Immunology, McGill University, Montreal, Quebec, Canada

^dAffaires Médicales et Innovation, Héma-Québec, Montreal, Quebec, Canada

^eCHU Ste-Justine, Montreal, Quebec, Canada

^fDépartement de Médecine, Université de Montréal, Montreal, Quebec, Canada

Guillaume Beaudoin-Bussières, Annemarie Laumaea, Sai Priya Anand, Jérémie Prévost, and Romain Gasser contributed equally to this article. Author order was determined in order of increasing seniority of the project.

ABSTRACT In the absence of effective vaccines and with limited therapeutic options, convalescent plasma is being collected across the globe for potential transfusion to coronavirus disease 2019 (COVID-19) patients. The therapy has been deemed safe, and several clinical trials assessing its efficacy are ongoing. While it remains to be formally proven, the presence of neutralizing antibodies is thought to play a positive role in the efficacy of this treatment. Indeed, neutralizing titers of $\geq 1:160$ have been recommended in some convalescent plasma trials for inclusion. Here, we performed repeated analyses at 1-month intervals on 31 convalescent individuals to evaluate how the humoral responses against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Spike glycoprotein, including neutralization, evolve over time. We observed that the levels of receptor-binding-domain (RBD)-specific IgG and IgA slightly decreased between 6 and 10 weeks after the onset of symptoms but that RBD-specific IgM levels decreased much more abruptly. Similarly, we observed a significant decrease in the capacity of convalescent plasma to neutralize pseudoparticles bearing wild-type SARS-CoV-2 S or its D614G variant. If neutralization activity proves to be an important factor in the clinical efficacy of convalescent plasma transfer, our results suggest that plasma from convalescent donors should be recovered rapidly after resolution of symptoms.

IMPORTANCE While waiting for an efficient vaccine to protect against SARS-CoV-2 infection, alternative approaches to treat or prevent acute COVID-19 are urgently needed. Transfusion of convalescent plasma to treat COVID-19 patients is currently being explored; neutralizing activity in convalescent plasma is thought to play a central role in the efficacy of this treatment. Here, we observed that plasma neutralization activity decreased a few weeks after the onset of the symptoms. If neutralizing activity is required for the efficacy of convalescent plasma transfer, our results suggest that convalescent plasma should be recovered rapidly after the donor recovers from active infection.

KEYWORDS coronavirus, COVID-19, SARS-CoV-2, Spike glycoproteins, RBD, ELISA, IgA, IgM, IgG, neutralization, cross-reactivity, convalescent plasma

Citation Beaudoin-Bussières G, Laumaea A, Anand SP, Prévost J, Gasser R, Goyette G, Medjahed H, Perreault J, Tremblay T, Lewin A, Gokool L, Morrissette C, Bégin P, Tremblay C, Martel-Laferrrière V, Kaufmann DE, Richard J, Bazin R, Finzi A. 2020. Decline of humoral responses against SARS-CoV-2 Spike in convalescent individuals. *mBio* 11:e02590-20. <https://doi.org/10.1128/mBio.02590-20>.

Invited Editor David D. Ho, Columbia University Medical Center

Editor Stephen P. Goff, Columbia University/HHMI

Copyright © 2020 Beaudoin-Bussières et al. This is an open-access article distributed under the terms of the [Creative Commons Attribution 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

Address correspondence to Andrés Finzi, andres.finzi@umontreal.ca.

Received 10 September 2020

Accepted 29 September 2020

Published 16 October 2020

Until an efficient vaccine to protect against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection becomes available, alternative approaches to treat or prevent acute coronavirus disease 2019 (COVID-19) are urgently needed. A promising approach is the use of convalescent plasma containing anti-SARS-CoV-2 antibodies (Abs) collected from donors who have recovered from COVID-19 (1). Convalescent plasma therapy has been successfully used in the treatment of SARS, Middle East respiratory syndrome (MERS), and influenza virus H1N1 pandemics and was previously shown to be associated with improvement of clinical outcomes (2–4). Experience to date has shown that the passive transfer of convalescent plasma to acute COVID-19 patients is well tolerated and presented some hopeful signs (5–9). In one study, the convalescent plasma used had high titers of IgG to SARS-CoV-2 (at least $\geq 1:640$), which correlated positively with neutralizing activity (10). While it remains to be formally demonstrated, neutralizing activity is considered an important determinant of convalescent plasma efficacy (11) and regulatory agencies have been recommending specific thresholds for qualifying convalescent plasma prior to its release. While neutralizing function has been associated with protection against reinfection in rhesus macaques (12), other antibody functions may be relevant for controlling an acute infection and should be examined to better understand the correlates of convalescent plasma-mediated efficacy (7).

It was recently reported that the humoral responses against SARS-CoV-2 are built rapidly, peaking at week 2 or week 3 after the onset of symptoms but steadily decreasing thereafter (13–15). Moreover, in a previous cross-sectional study, we reported that the neutralization capacity decreased between the third and the sixth week after the onset of symptoms (14). Since convalescent patients are generally required to wait for 14 days after recovery to start plasma donations and since they may donate plasma multiple times in the ensuing weeks, most donations are likely to occur even later than this. Whether the neutralization capacity of convalescent plasma is stabilized after 6 weeks or decreases further remains unknown. To address this issue, which might have practical implications for the selection of plasma from convalescent donors, we analyzed serological samples from 31 convalescent donors that were collected at 6 and 10 weeks after the onset of symptoms.

All of the convalescent donors initially tested positive for SARS-CoV-2 by reverse transcriptase PCR (RT-PCR) on nasopharyngeal specimens, with complete resolution of symptoms for at least 14 days before blood sampling. The average age of the donors (22 males and 9 females) was 46 years. We collected plasma samples from each individual at two time points: 6 weeks after the onset of symptoms (baseline; median, 43 days) and 4 weeks after (1 month; median, 74 days after the onset of symptoms) (Table 1).

We first evaluated the presence of receptor-binding-domain (RBD)-specific IgG, IgM, and IgA antibodies by enzyme-linked immunosorbent assay (ELISA) as we had recently described (14). In agreement with a recent report (16, 23), we observed that all RBD-specific IgG, IgM, and IgA titers significantly decreased between 6 and 10 weeks after the onset of symptoms. We noted that IgM and IgA titers diminished significantly more abruptly than IgG titers (Fig. 1). Accordingly, the proportions of convalescent individuals presenting detectable titers of IgM and IgA decreased by $\sim 13\%$ and $\sim 25\%$, respectively, at 10 weeks after the onset of symptoms (Fig. 1B and C) whereas the percentage of infected individuals presenting detectable titers of IgG remained stable (Fig. 1A).

TABLE 1 Cohort characteristics

| Median no. of days (range) after onset of symptoms and first sample collection: baseline | Median no. of days (range) after onset of symptoms and second sample collection (1 mo) | Avg age of individuals in yrs (range) | No. of individuals | |
|--|--|---------------------------------------|--------------------|------------|
| | | | Male (n) | Female (n) |
| 43 (16–60) | 74 (44–87) | 46 (20–67) | 22 | 9 |




FIG 1 SARS-CoV-2 S-specific and RBD-specific antibody levels decrease over time. (A to C) Indirect ELISA was performed using recombinant SARS-CoV-2 RBD and incubation with plasma samples recovered at baseline (6 weeks after the onset of symptoms; red circle) and 1 month later (black circle). Anti-RBD antibody binding was detected using (A) anti-IgG-HRP (anti-IgG horseradish peroxidase), (B) anti-IgM-HRP, or (C) anti-IgA-HRP. Relative light unit (RLU) values obtained with bovine serum albumin (BSA) (negative control) were subtracted and further normalized to the signal obtained with the anti-RBD CR3022 monoclonal antibodies (MAb) present in each plate. The graphs shown in panels A to C represent (A and B) the areas under the curve (AUC) calculated from RLU obtained with serial plasma dilutions or (C) the normalized RLU for one plasma dilution (1:500). (D to F) Cell surface staining of 293T cells expressing full-length Spike (S) from different HCoVs, including (D) SARS-CoV-2 or its D614G counterpart; (E) SARS-CoV; and (F) OC43, NL63, and 229E with plasma samples recovered at baseline (6 weeks after the onset of symptoms) and 1 month later. The graphs shown in panels D to F represent median fluorescence intensities (MFI). In panels A to F, undetectable levels are represented as white symbols, and limits of detection are plotted. The average numbers and percentages of positive samples are indicated at the top of each panel. Statistical significance was tested using Wilcoxon matched-pair signed-rank tests (ns, not significant; **, $P < 0.01$; ****, $P < 0.0001$).

We next used flow cytometry to examine the ability of convalescent plasma to recognize the full-length SARS-CoV-2 Spike protein expressed at the cell surface. Briefly, 293T cells expressing SARS-CoV-2 S glycoproteins were stained with plasma samples, followed by incubation with secondary antibodies recognizing all antibody isotypes. Since the SARS-CoV-2 strain circulating in Europe and North America has the D614G mutation (17), we also evaluated recognition of this variant by flow cytometry. As presented in Fig. 1D, convalescent plasma from 96.8% of donors (all but one) recognized both SARS-CoV-2 S variants (wild type [WT] and D614G) at baseline. While this percentage was found to have remained stable 4 weeks later, the level of recognition (mean fluorescence intensity [MFI]) was significantly diminished for both WT and D614G S-expressing cells, indicating that Spike-reactive antibodies were less abundant in convalescent plasma collected at this later time point. Interestingly, the MFI values




FIG 2 Neutralizing activity of convalescent plasma decreases over time. (A) Pseudoviral particles coding for the luciferase reporter gene and bearing SARS-CoV-2 S glycoprotein or its D614G counterpart, SARS-CoV S glycoprotein, or VSV-G glycoprotein were used to infect 293T-ACE2 cells. Pseudoviruses were incubated (37°C, 1 h) with serial dilutions of plasma samples recovered at baseline (6 weeks after the onset of symptoms) or collected 1 month later prior to infection of 293T-ACE2 cells. Infectivity at each dilution was assessed in duplicate, and data are shown as the percentage of infection without plasma for each pseudovirus. (B) The median of neutralization for baseline (red) or 1-month (black) plasma samples is shown. (C) Neutralization half-maximal inhibitory plasma dilution (ID₅₀) values were determined using a normalized nonlinear regression with GraphPad Prism software. Undetectable levels (ID₅₀ < 50) are represented as white symbols. The mean neutralizing titers and the proportions (%) of neutralizers (patients with an ID₅₀ value over 50) are shown above the graphs. Statistical significance was tested using Wilcoxon matched-pair signed-rank tests (ns, not significant; ****, $P < 0.0001$).

were almost identical for the cells expressing the WT S and those expressing the D614G variant S (7,206 and 7,024, respectively; Fig. 1D), suggesting that the mutation did not significantly affect the S conformation. In agreement with recent work, we observed that SARS-CoV-2-elicited antibodies cross-reacted with human sarbecoviruses (14) (SARS-CoV; Fig. 1E) and with another betacoronavirus (OC43) whereas no cross-reactive antibodies to alphacoronavirus (NL63 and 229E) S glycoproteins (Fig. 1F) were detected. Levels of cross-reactive antibodies recognizing SARS-CoV and OC43 S glycoproteins decreased between the two time points, following a trend similar to that shown by the SARS-CoV-2 S-reactive antibodies (Fig. S1).

We next measured the capacity of plasma samples to neutralize pseudoparticles bearing WT SARS-CoV-2 S, its D614G variant, or vesicular stomatitis virus G (VSV-G) glycoproteins using 293T cells stably expressing ACE2 as target cells (Fig. 2). Previous studies demonstrated that the neutralizing activity of convalescent plasma measured with this method correlates quantitatively with neutralizing activity measured using an authentic SARS-CoV-2 neutralization assay (18, 19). Neutralizing activity against SARS-CoV-2 WT or D614G S glycoprotein, as measured by the neutralization half-maximum inhibitory dilution (ID₅₀), was detected in 71% of patients 6 weeks after the onset of symptoms. While we acknowledge that the sensitivity of any given neutralization assay

could affect calculations of the percentage of donors with neutralization activity, we note that the percentage of convalescent plasma with undetectable neutralization titers reported here is similar to what was reported in recent studies (11, 20, 21). SARS-CoV-2 neutralization was specific since no neutralization was observed against pseudoparticles expressing VSV-G (Fig. 2). Neutralizing activity against pseudoparticles bearing the SARS-CoV S glycoprotein was detected in only 25% of convalescent plasma and exhibited low potency, as previously reported (Fig. 2) (14). As recently shown, plasma samples from prepandemic SARS-CoV-2-negative and SARS-CoV-negative individuals showed no neutralization activity against pseudoparticles bearing the SARS-CoV-2 or SARS-CoV Spike protein (not shown). Of note, while we observed enhanced infectivity for the D614G variant compared to its WT SARS-CoV-2 S counterpart (see Fig. S2A in the supplemental material), no major differences in neutralization with convalescent plasma were detected at either time point (Fig. S2B), thus suggesting that the D614G change does not affect the overall conformation of the Spike, in agreement with recent findings (17, 22).

The capacity to neutralize SARS-CoV-2 S WT- or D614G-pseudotyped particles significantly correlated with the presence of RBD-specific IgG, IgM, IgA, and anti-S antibodies (Fig. S3). Interestingly, we observed a pronounced (20% to 30%) decrease in the proportion of convalescent individuals able to neutralize pseudoparticles bearing SARS-CoV-2 S glycoprotein between 6 and 10 weeks after the onset of symptoms. Moreover, with plasma that still neutralized, the neutralization activity significantly decreased between these two time points (Fig. 2C). Interestingly, RBD-specific IgM and neutralizing activity declined more significantly in convalescent plasma over time than RBD-specific IgG, IgA, and anti-S Ab activity (Fig. S4A and B). Moreover, while the loss of neutralizing activity on the WT and D614G pseudoparticles over time correlated with the loss of anti-RBD IgM, IgA, and IgG antibodies, the correlation was higher for IgM than for IgG and IgA (Fig. S4C and D), suggesting that at least part of the neutralizing activity could be mediated by IgM, as recently proposed (13, 14). Therefore, if plasma neutralization activity is shown to be required for protection from SARS-CoV-2 infection, then our results suggest that this protection could be limited in time and that, in the context of vaccination, multiple boosts might be necessary to mount a durable and effective anti-SARS-CoV-2 humoral response.

In summary, our results indicate that plasma neutralization activity continues decreasing past the sixth week of symptom onset (14). It is currently unknown whether neutralizing activity truly drives the efficacy of convalescent plasma in acute COVID-19. If this were to be found to be the case, our results suggest that efforts should be made to ensure that convalescent plasma is collected as soon as possible after recovery of the donor from active infection.

SUPPLEMENTAL MATERIAL

Supplemental material is available online only.

TEXT S1, DOCX file, 0.1 MB.

FIG S1, PDF file, 0.4 MB.

FIG S2, PDF file, 0.4 MB.

FIG S3, PDF file, 0.4 MB.

FIG S4, PDF file, 1 MB.

ACKNOWLEDGMENTS

We thank the convalescent plasma donors who participated in this study; the Héma-Québec team involved in convalescent donor recruitment and plasma collection; the staff members of the CRCHUM BSL3 and Flow Cytometry Platforms for technical assistance; Stefan Pöhlmann (Georg-August University, Germany) for the plasmids coding for SARS-CoV-2 S, 229E S and NL63 S glycoproteins; Marcelline Côté (University of Ottawa) for the OC43 S expressor; and M. Gordon Joyce (U.S. Military HIV Research Program [MHRP]) for the CR3022 monoclonal antibody.

This work was supported by le Ministère de l'Économie et de l'Innovation du

Qu ebec, Program de soutien aux organismes de recherche et d'innovation (A. Finzi), by the Fondation du CHUM (A. Finzi), and by the Canadian Institutes of Health Research (via the Immunity Task Force), the American Foundation for AIDS Research (amfAR) (A. Finzi and D. E. Kaufmann). This work was also supported by CIHR Foundation grant 352417 to A. Finzi and by CIHR COVID-19 Rapid Research Funding to A. Finzi, R. Bazin, and P. B egin. A. Finzi is the recipient of a Canada Research Chair on Retroviral Entry (RCHS0235 950-232424). G. Beaudoin-Bussi eres, S. P. Anand, and J. Pr evost are supported by CIHR fellowships. R. Gasser is supported by a MITACS Acc el eration postdoctoral fellowship. V. Martel-Laferr iere and P. B egin are supported by FRQS salary awards. D. E. Kaufmann is a FRQS Merit Research Scholar. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

We declare no competing interests.

REFERENCES

- Chen L, Xiong J, Bao L, Shi Y. 2020. Convalescent plasma as a potential therapy for COVID-19. *Lancet Infect Dis* 20:398–400. [https://doi.org/10.1016/S1473-3099\(20\)30141-9](https://doi.org/10.1016/S1473-3099(20)30141-9).
- Ko JH, Seok H, Cho SY, Ha YE, Baek JY, Kim SH, Kim YJ, Park JK, Chung CR, Kang ES, Cho D, Muller MA, Drosten C, Kang CI, Chung DR, Song JH, Peck KR. 2018. Challenges of convalescent plasma infusion therapy in Middle East respiratory coronavirus infection: a single centre experience. *Antivir Ther* 23:617–622. <https://doi.org/10.3851/IMP3243>.
- Hung IF, To KK, Lee CK, Lee KL, Chan K, Yan WW, Liu R, Watt CL, Chan WM, Lai KY, Koo CK, Buckley T, Chow FL, Wong KK, Chan HS, Ching CK, Tang BS, Lau CC, Li IW, Liu SH, Chan KH, Lin CK, Yuen KY. 2011. Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection. *Clin Infect Dis* 52:447–456. <https://doi.org/10.1093/cid/ciq106>.
- Cheng Y, Wong R, Soo YO, Wong WS, Lee CK, Ng MH, Chan P, Wong KC, Leung CB, Cheng G. 2005. Use of convalescent plasma therapy in SARS patients in Hong Kong. *Eur J Clin Microbiol Infect Dis* 24:44–46. <https://doi.org/10.1007/s10096-004-1271-9>.
- Bloch EM, Shoham S, Casadevall A, Sachais BS, Shaz B, Winters JL, van Buskirk C, Grossman BJ, Joyner M, Henderson JP, Pekosz A, Lau B, Wesolowski A, Katz L, Shan H, Auwaerter PG, Thomas D, Sullivan DJ, Paneth N, Gehrie E, Spitalnik S, Hod EA, Pollack L, Nicholson WT, Pirofski LA, Bailey JA, Tobian AA. 2020. Deployment of convalescent plasma for the prevention and treatment of COVID-19. *J Clin Invest* 130:2757–2765. <https://doi.org/10.1172/JCI138745>.
- Casadevall A, Joyner MJ, Pirofski LA. 2020. A randomized trial of convalescent plasma for COVID-19-potentially hopeful signals. *JAMA* 324:455. <https://doi.org/10.1001/jama.2020.10218>.
- Casadevall A, Pirofski LA. 2020. The convalescent sera option for containing COVID-19. *J Clin Invest* 130:1545–1548. <https://doi.org/10.1172/JCI138003>.
- Joyner MJ, Wright RS, Fairweather D, Senefeld JW, Bruno KA, Klassen SA, Carter RE, Klompas AM, Wiggins CC, Shepherd JR, Rea RF, Whelan ER, Clayburn AJ, Spiegel MR, Johnson PW, Lesser ER, Baker SE, Larson KF, Ripoll JG, Andersen KJ, Hodge DO, Kunze KL, Buras MR, Vogt MN, Herasevich V, Dennis JJ, Regimbal RJ, Bauer PR, Blair JE, van Buskirk CM, Winters JL, Stubbs JR, Paneth NS, Verdun NC, Marks P, Casadevall A. 2020. Early safety indicators of COVID-19 convalescent plasma in 5,000 patients. *J Clin Invest* <https://doi.org/10.1172/JCI140200>.
- Duan K, Liu B, Li C, Zhang H, Yu T, Qu J, Zhou M, Chen L, Meng S, Hu Y, Peng C, Yuan M, Huang J, Wang Z, Yu J, Gao X, Wang D, Yu X, Li L, Zhang J, Wu X, Li B, Xu Y, Chen W, Peng Y, Hu Y, Lin L, Liu X, Huang S, Zhou Z, Zhang L, Wang Y, Zhang Z, Deng K, Xia Z, Gong Q, Zhang W, Zheng X, Liu Y, Yang H, Zhou D, Yu D, Hou J, Shi Z, Chen S, Chen Z, Zhang X, Yang X. 2020. Effectiveness of convalescent plasma therapy in severe COVID-19 patients. *Proc Natl Acad Sci U S A* 117:9490–9496. <https://doi.org/10.1073/pnas.2004168117>.
- Li L, Zhang W, Hu Y, Tong X, Zheng S, Yang J, Kong Y, Ren L, Wei Q, Mei H, Hu C, Tao C, Yang R, Wang J, Yu Y, Guo Y, Wu X, Xu Z, Zeng L, Xiong N, Chen L, Wang J, Man N, Liu Y, Xu H, Deng E, Zhang X, Li C, Wang C, Su S, Zhang L, Wang J, Wu Y, Liu Z. 2020. Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19: a randomized clinical trial. *JAMA* 324:460. <https://doi.org/10.1001/jama.2020.10044>.
- Robbiani DF, Gaebler C, Muecksch F, Lorenzi JCC, Wang Z, Cho A, Agudelo M, Barnes CO, Gazumyan A, Finkin S, Hagglof T, Oliveira TY, Viant C, Hurley A, Hoffmann HH, Millard KG, Kost RG, Cipolla M, Gordon K, Bianchini F, Chen ST, Ramos V, Patel R, Dizon J, Shimeliovich I, Mendoza P, Hartweiger H, Nogueira L, Pack M, Horowitz J, Schmidt F, Weisblum Y, Michailidis E, Ashbrook AW, Waltari E, Pak JE, Huey-Tubman KE, Koranda N, Hoffman PR, West AP, Jr, Rice CM, Hatziioannou T, Bjorkman PJ, Bieniasz PD, Caskey M, Nussenzweig MC. 2020. Convergent antibody responses to SARS-CoV-2 in convalescent individuals. *Nature* 584:437–442. <https://doi.org/10.1038/s41586-020-2456-9>.
- Deng W, Bao L, Liu J, Xiao C, Liu J, Xue J, Lv Q, Qi F, Gao H, Yu P, Xu Y, Qu Y, Li F, Xiang Z, Yu H, Gong S, Liu M, Wang G, Wang S, Song Z, Liu Y, Zhao W, Han Y, Zhao L, Liu X, Wei Q, Qin C. 2020. Primary exposure to SARS-CoV-2 protects against reinfection in rhesus macaques. *Science* 369:818–823. <https://doi.org/10.1126/science.abc5343>.
- Sterlin D, Mathian A, Miyara M, Mohr A, Anna F, Claer L, Quentric P, Fadlallah J, Ghillani P, Gunn C, Hockett R, Mudumba S, Guihot A, Luyt C-E, Mayaux J, Beurton A, Fourati S, Lacorte J-M, Yssel H, Parizot C, Dorgham K, Charneau P, Amoura Z, Gorochov G. 2020. IgA dominates the early neutralizing antibody response to SARS-CoV-2. *medRxiv* <https://doi.org/10.1101/2020.06.10.20126532>.
- Pr evost J, Gasser R, Beaudoin-Bussi eres G, Richard J, Duerr R, Laumaea A, Anand SP, Goyette G, Benlarbi M, Ding S, Medjahed H, Lewin A, Perreault J, Tremblay T, Gendron-Lepage G, Gauthier N, Carrier M, Marcoux D, Pich e A, Lavoie M, Benoit A, Loungnarath V, Brochu G, Haddad E, Stacey HD, Miller MS, Desforges M, Talbot PJ, Gould Maule GT, C ot e M, Therrien C, Serhir B, Bazin R, Roger M, Finzi A. 2020. Cross-sectional evaluation of humoral responses against SARS-CoV-2 Spike. *Cell Reports Medicine*. <https://doi.org/10.1016/j.xcrm.2020.100126>.
- Adams ER, Ainsworth M, Anand R, Andersson MI, Auckland K, Baillie JK, Barnes E, Beer S, Bell J, Berry T, Bibi S, Carroll M, Chinnakannan S, Clutterbuck E, Cornall RJ, Crook DW, De Silva T, Dejnirattisai W, Dingle KE, Dold C, Espinosa A, Eyre DW, Farmer H, Fernandez Mendoza M, Georgiou D, Hoosdally SJ, Hunter A, Jeffrey K, Klenerman P, Knight J, Knowles C, Kwok AJ, Leuschner U, Levin R, Liu C, Lopez-Camacho C, Martinez Garrido JC, Matthews PC, McGivern H, Mentzer AJ, Milton J, Mongkolsapaya J, Moore SC, Oliveira MS, Pereira F, Perez Lopez E, Peto T, Ploegh RJ, et al. 2020. Antibody testing for COVID-19: a report from the National COVID Scientific Advisory Panel. *medRxiv* <https://doi.org/10.1101/2020.04.15.20066407>.
- Long QX, Tang XJ, Shi QL, Li Q, Deng HJ, Yuan J, Hu JL, Xu W, Zhang Y, Lv FJ, Su K, Zhang F, Gong J, Wu B, Liu XM, Li JJ, Qiu JF, Chen J, Huang AL. 2020. Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections. *Nat Med* 26:1200–1204. <https://doi.org/10.1038/s41591-020-0965-6>.
- Korber B, Fischer WM, Gnanakaran S, Yoon H, Theiler J, Abfalterer W, Hengartner N, Giorgi EE, Bhattacharya T, Foley B, Hastie KM, Parker MD, Partridge DG, Evans CM, Freeman TM, de Silva TI, on behalf of the Sheffield COVID-19 Genomics Group, McDanal C, Perez LG, Tang H, Moon-Walker A, Whelan SP, LaBranche CC, Saphire EO, Montefiori DC. 2 July 2020. Tracking changes in SARS-CoV-2 Spike: evidence that D614G

- increases infectivity of the COVID-19 virus. *Cell*. <https://doi.org/10.1016/j.cell.2020.06.043>.
18. Schmidt F, Weisblum Y, Muecksch F, Hoffmann HH, Michailidis E, Lorenzi JCC, Mendoza P, Rutkowska M, Bednarski E, Gaebler C, Agudelo M, Cho A, Wang Z, Gazumyan A, Cipolla M, Caskey M, Robbiani DF, Nussenzweig MC, Rice CM, Hatzioannou T, Bieniasz PD. 2020. Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses. *J Exp Med* 217:e20201181. <https://doi.org/10.1084/jem.20201181>.
 19. Jackson LA, Anderson EJ, Roupael NG, Roberts PC, Makhene M, Coler RN, McCullough MP, Chappell JD, Denison MR, Stevens LJ, Pruijssers AJ, McDermott A, Flach B, Doria-Rose NA, Corbett KS, Morabito KM, O'Dell S, Schmidt SD, Swanson PA, Il, Padilla M, Mascola JR, Neuzil KM, Bennett H, Sun W, Peters E, Makowski M, Albert J, Cross K, Buchanan W, Pikaart-Tautges R, Ledgerwood JE, Graham BS, Beigel JH, m RNASG. 2020. An mRNA vaccine against SARS-CoV-2 - preliminary report. *N Engl J Med* <https://doi.org/10.1056/NEJMoa2022483>.
 20. Seow J, Graham C, Merrick B, Acors S, Steel KJA, Hemmings O, O'Bryne A, Kouphou N, Pickering S, Galao R, Betancor G, Wilson HD, Signell AW, Winstone H, Kerridge C, Temperton N, Snell L, Bisnauthsing K, Moore A, Green A, Martinez L, Stokes B, Honey J, Izquierdo-Barras A, Arbane G, Patel A, O'Connell L, O Hara G, MacMahon E, Douthwaite S, Nebbia G, Batra R, Martinez-Nunez R, Edgeworth JD, Neil SJD, Malim MH, Doores K. 2020. Longitudinal evaluation and decline of antibody responses in SARS-CoV-2 infection. medRxiv <https://doi.org/10.1101/2020.07.09.20148429>.
 21. Payne DC, Smith-Jeffcoat SE, Nowak G, Chukwuma U, Geibe JR, Hawkins RJ, Johnson JA, Thornburg NJ, Schiffer J, Weiner Z, Bankamp B, Bowen MD, MacNeil A, Patel MR, Deussing E, CDC COVID-19 Surge Laboratory Group, Gillingham BL. 2020. SARS-CoV-2 infections and serologic responses from a sample of U.S. Navy service members - USS Theodore Roosevelt, April 2020. *MMWR Morb Mortal Wkly Rep* 69:714-721. <https://doi.org/10.15585/mmwr.mm6923e4>.
 22. Zhang L, Jackson CB, Mou H, Ojha A, Rangarajan ES, Izard T, Farzan M, Choe H. 2020. The D614G mutation in the SARS-CoV-2 spike protein reduces S1 shedding and increases infectivity. bioRxiv <https://doi.org/10.1101/2020.06.12.148726>.
 23. Perreault J, Tremblay T, Fournier MJ, Drouin M, Beaudoin-Bussi eres G, Pr evost J, Lewin A, B egin P, Finzi A, Bazin R. 1 October 2020. Waning of SARS-CoV-2 RBD antibodies in longitudinal convalescent plasma samples within four months after symptom onset. *Blood*. <https://doi.org/10.1182/blood.202008367>.